newsfilter
← Latest News
Business Wire·

Multidisciplinary Physician Panel to Share Real-World Benefits of bioAffinity Technologies' Noninvasive CyPath Lung Cancer Test in Upcoming Society for Advanced Bronchoscopy Webinar

BIAFBIAFW
  • bioAffinity Technologies announced a Society for Advanced Bronchoscopy webinar on June 16 at 7 p.m. ET to discuss CyPath® Lung's role in lung cancer detection & management.
  • The webinar titled "Navigating Lower Cancer-Risk Nodules in High-Risk Patients with Noninvasive CyPath® Lung Testing" will feature Dr. Vijay K. Gunuganti, Dr. Reginald Carl Baptiste, & Dr. Sai Karan Vamsi Guda moderated by Dr. Robert Sussman.
  • CyPath® Lung is a noninvasive test using automated flow cytometry & artificial intelligence to analyze sputum for lung cancer markers in high-risk patients.
  • Clinical trial data shows CyPath® Lung achieved 92% sensitivity, 87% specificity, 88% accuracy, & 99% negative predictive value for detecting lung cancer in patients with nodules under 20 millimeters.
  • The test aids in risk stratification for indeterminate lung nodules, supports surgical decision-making, lowers healthcare costs by reducing unnecessary invasive procedures, & supports surveillance for cancer recurrence.
  • CyPath® Lung is marketed as a Laboratory Developed Test (LDT) overseen under CLIA regulations & is intended to be used alongside other clinical findings rather than as a sole diagnostic tool.
  • The event is open to clinicians, healthcare professionals, & the public, with registration available via a provided link.